KDR and glioblastoma: These findings underscore the potential use of 64Cu-GO-VEGF-121 as a highly stable, tumor-specific imaging agent capable of efficiently targeting VEGFR in the U87MG glioblastoma model, which is superior to the passive targeting strategy typically observed in current GO nanoconjugates.